low accrual

The purpose of this study is to examine the use of MRI surveillance for patients with no prostate cancer, potential prostate cancer, or diagnosed low-grade prostate cancer.

This study will use MRI instead of prostate biopsy in combination with regularly scheduled urologist visits, interval PSA checks, and annual DRE to help establish a non-invasive method for 1) participants with a negative prostate MRI (PI-RADS 1 or 2) who have never had a biopsy; 2) participants with a positive MRI (PI-RADS score of 3, 4, or 5) and negative MRI-targeted biopsy pathology; and 3) monitoring participants with clinically diagnosed low risk prostate cancer who are on active surveillance. However, if at any point, clinical suspicion indicated either by the presence of suspicious lesions on the MRI, rising PSA, and/or positive DRE arises, then an immediate biopsy will be performed.

Inclusion Criteria:

• Biopsy-naive patients with a negative prostate MRI (PI-RADS score 1 or 2); or
• Patients with a PI-RADS score of 3, 4, or 5 on MRI and a negative MR-targeted biopsy; or
• Patients on active surveillance with a negative prostate MRI (PI-RADS 1 or 2).

Exclusion Criteria:

• Positive DRE;
• PSA > 10 ng/ml or unstable PSA (doubling time <3 years) during the last year prior to enrolling in this study;
• PSAD > 0.15 (calculated using most recent PSA divided by MRI prostate volume);
• First degree relative diagnosed with prostate cancer
• First degree relative diagnosed with a BRCA2 or Lynch syndrome associated gene causing any cancer.
• Patient carries a mutation on BRCA2 or a mismatch repair gene associated with Lynch syndrome (MLHl, MSH2, MSH6, PMS2); known BRCA2 or known mismatch repair gene mutation in the family (Lynch Syndrome) and patient has not had testing; or family history consistent with BRCA2 or Lynch syndrome and there is no known BRCA2 or mismatch repair gene in the family.

Individual participant data that underlie the results reported in the published article, after deidentification (text, tables, figures).

Beginning 9 months and ending 36 months following article publication

To be shared with investigators whose proposed use of the data has been approved by an independent review committee ("learned intermediary") identified for this purpose.

For individual participant data meta-analysis